SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention ahead of quarterly results, with investors focused on whether ORLADEYOs growth can support the stock while the company waits for pipeline progress, especially Navenibart data. The conversation is divided between bullish views that recurring revenue and future HAE treatments are undervalued and frustration over weak share performance, dilution, competition, and managements acquisition-focused strategy.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Discussion centers on CADLs planned Q4 BLA submission for CAN-2409 in localized prostate cancer and upcoming clinical-data presentations, including at SITC. Optimism about the Phase 3 results and pipeline is offset by frustration over the share-price decline, with traders debating macro biotech weakness, CEO share sales, possible dilution, and whether the filing will stay on schedule.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

Alnylams post-earnings selloff is centered on concerns that Amvuttra demand is slowing and TTR sales guidance has been trimmed, despite strong product growth; traders also question how much the reported profit reflects a one-time tax benefit rather than durable earnings. The reaction is sharply divided between criticism of management and further downside risk versus dip-buyers who view the drop as an overreaction to commercial growth concerns and delayed pipeline updates.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs record October deliveries and rapid overseas growth are drawing attention, but traders are focused on whether November and December can sustain the pace needed to meet the Q4 goal. Reactions are mixed: some see momentum in expanding sales, while others question execution, margins and the impact of intense China EV competition as the stock remains under pressure.

Interactive Brokers Group, Inc. is an investment holding company, which engages in broker or dealer and proprietary trading businesses. It offers custody and service accounts for hedge and mutual funds, exchange-traded funds, registered investment advisors, proprietary trading groups, introducing brokers, and individual investors. The company was founded by Thomas Pechy Peterffy in 1977 and is headquartered in Greenwich, CT.

Interactive Brokers Group Inc - Ordinary Shares - Class A

Interactive Brokers Group Inc 

Interactive Brokers quarterly results are driving discussion, with traders weighing strong account growth and net interest income against softer trading activity. Reactions are split: some see a solid business update, while others are frustrated that the shares fell despite results broadly meeting expectations.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

Traders are using SCO to bet on a pullback in crude oil, often citing hopes for Iran de-escalation and restored shipping through the Strait of Hormuz, while continued regional tensions keep oil-price expectations volatile. Many also complain that SCOs leveraged daily reset and futures-curve effects have eroded returns or made it track oil declines poorly.

Avalanche (AVAX) is a cryptocurrency launched in 2020. Avalanche has a current supply of 470,674,773.0976502 with 444,005,973.0976502 in circulation. The last known price of Avalanche is 8.56026703 USD and is up 0.21 over the last 24 hours. It is currently trading on 1132 active market(s) with $277,939,674.22 traded over the last 24 hours. More information can be found at https://avax.network/.

Avalanche

AVAX is drawing attention after a sharp rally that traders link to growing institutional and real-world-asset tokenization activity on Avalanche, including discussion of a Goldman Sachs treasury fund on an AVAX-based network. Bulls see a breakout and renewed adoption narrative, while skeptics call the move speculative and warn that gains may fade.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA approval of Inovios competing RRP treatment has put pressure on Precigens PAPZIMEOS and raised questions about future market share. Traders debate the threat: some emphasize Inovios potential to reduce surgery burden, while others cite PAPZIMEOSs first-mover position, full approval, and established commercial and reimbursement setup.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbines decision to delay its quarterly results by a week to finalize financial statements has driven a sharp selloff. Traders are divided over whether the postponement is a routine procedural issue or a warning sign about the results or accounting, with no resolution confirmed.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

ARMs steep decline is being discussed alongside a broader semiconductor and AI-stock selloff, with Intels weak outlook cited by some traders as adding pressure. The debate centers on whether the drop reflects an overdue valuation reset and concerns about CPU competition, or a buying opportunity given Arms role in AI and data-center computing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results

Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial ResultsPR NewswireNEW HAVEN, Conn., Oct. 29, 2026 The US Food and Drug Administration (FDA) accepted new drug application...

Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 43.5% in Biohaven Ltd. (BHVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy

Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively...

The Next Big Moves Include a Short-Interest Setup and Other Stocks Investors Are Watching

Today’s market spotlight spans companies navigating critical catalysts; NeOnc Technologies Holdings (NASDAQ:NTHI) is drawing attention with brain-cancer research milestones and a closely watched technical rebound setup; BIO-key International, (NASDAQ:BKYI) is expanding its government cybersecurity footprint in the Gulf; STAK (NASDAQ:STAK) is working to build on a return to profitability; Biohaven (NYSE:BHVN) faces pivotal clinical and regulatory questions across its drug pipeline; Exascale Labs Holdings (NASDAQ:XLAB) is pursuing AI infrastructure growth following a multimillion-dollar GPU server agreement; and WISeSat.Space (NASDAQ:SAIQ) is advancing satellite-based cybersecurity and post-quantum communications.

BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia 

Equity

The U.S. Food and Drug Administration accepted Biohaven’s resubmitted application for its experimental neurological disease drug, Vyglxia.


12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers

Biohaven (NYSE:BHVN) shares increased by 39.3% to $16.37 during Thursday's pre-market session. The company's market cap stands at $1.7 billion.
Vogenx (NASDAQ:VOGX) stock rose 22.05% to $24.89. Theread more...

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights

Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents. 


Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select...

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx...

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN) Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)PR NewswireNEW YORK, Sept. 11, 2026Biohaven shares gave up nearly 15% in a single...

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Neutral Sentiment

<ul class="summary-bullets"><li>The FDA issued a Complete Response Letter last November, declining to approve the drug.</li><li>The FDA set a target deadline for the first quarter of 2027.</li><li>Biohaven held about $270.5 million in cash, marketable securities and restricted cash as of June 30.</li></ul>Shares of Biohaven (BHVN) ripped in pre-market trading on Thursday, after the biotech firm announced that the U.S. Food and Drug Administration (FDA) accepted its resubmitted application for its experimental neurological disease drug.<a class="mention" data-mention="$BHVN" data-symbol-id="BHVN" href="https://stocktwits.com/symbol/BHVN" target="_blank">BHVN shares</a> were up more than 36% at the time of writing, tracking their biggest single-day gain in more than four years.<h2 class="st-heading-2">Biohaven Gets A Second Chance</h2>This comes as a relief for Biohaven investors after the FDA issued a Complete Response Letter (CRL) last November, declining to approve the drug over concerns about the clinical evidence supporting its effectiveness. Vyglxia is an experimental oral treatment for spinocerebellar ataxia (SCA), a rare inherited neurological disease that affects balance, coordination, walking and speech.Although Biohaven reported that the drug slowed disease progression by 50% to 70% over a three-year period, the FDA raised concerns about flaws in the study design. Following the rejection, Biohaven announced plans to cut annual direct research and development spending by about 60%.The agency said the updated application, which includes additional positive analyses, adequately addresses its November rejection letter. The FDA has set a target deadline for the first quarter (Q1) of 2027, based on input from external stakeholders.<h2 class="st-heading-2">Biohaven’s Pipeline In Focus</h2>Beyond Vyglxia, Biohaven is developing BHV-1300 for Graves’ disease, an autoimmune thyroid disorder, and BHV-1400 for a kidney disease called IgA nephropathy. Its pipeline also includes Opakalim for epilepsy, Taldefgrobep alfa for obesity and BHV-1530 for cancer.Biohaven remains a clinical-stage company without commercial drug sales. It held about $270.5 million in cash, marketable securities and restricted cash as of June 30.<h2 class="st-heading-2">Retail Chatter Is Mixed</h2>Retail sentiment surrounding BHVN on Stocktwits flipped to ‘bullish’ from ‘neutral’ over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/BHVN_76428e168b.png" alt="BHVN.png">One user said the drug will not be a money maker even if it gets approval.<stembedurl>https://stocktwits.com/KimAntony/message/667097277</stembedurl>Another user called it “incredible news”<stembedurl>https://stocktwits.com/Timefortendies77/message/667096710</stembedurl>The stock has gained around 9% so far this year.Also read:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lmt-stock-lockheed-martin-q3-earnings-2026-outlook-f35-framework/cZxwewGRBwt">Lockheed Martin Raises 2026 Guidance, Unveils F-35 Production Plan With DOW – LMT Stock Set To Breach This Key Resistance After Nearly 2 Months</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Biohaven logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

The FDA issued a Complete Response Letter last November, declining to approve the drug.

Why Did BHVN Stock Surge 36% In Pre-Market Today?

Biohaven Pharmaceutical Holding Company Ltd

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$15.42
Prev Close	$16.49
Open	$15.46
Dividend Yield	0.00%
50-Day Moving Average	$13.62
Beta	1.59
Avg. Volume	3.05M
PE Ratio	-3.99

52-Week High	$18.24
52-Week Low	$7.48
Market Capitalization	$2.33B
EPS (Annual)	-$6.86
Price to Book	-23.71
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

BHVN Fundamentals